Q-omics provides the consensus-scored LHX2 profile across patient tissues and cancer cell-line models. LHX2 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LHX2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, LHX2 RNA expression shows 14,377 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, HNSC, and ACC as cancer lineages where LHX2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LHX2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LHX2 survival associations across molecular data types. LHX2 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LHX2 RNA expression–survival associations across cancer types. High LHX2 expression shows unfavorable associations in KIRC, ACC, MESO, BRCA and KIRP, but favorable associations in CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LHX2 RNA expression.
This table summarizes LHX2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for LHX2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LHX2 shows lower tumor expression in LIHC and higher tumor expression in HNSC, KIRP, LUSC, KIRC and BRCA. The HNSC box plot shows higher LHX2 RNA expression in tumor versus normal tissue (log2 FC = +1.461, t-test p < 0.001).
This table shows molecular features associated with LHX2 in patient tissues and cancer cell lines. In patient samples, LHX2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, LHX2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and UPPER_AERODIGESTIVE_TRACT.
